Tags

Type your tag names separated by a space and hit enter

Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy.
Eye Brain. 2016; 8:81-90.EB

Abstract

Retinopathy of prematurity (ROP) remains a leading cause of childhood blindness, affecting infants born prematurely. ROP is characterized by the onset of delayed physiological retinal vascular development (PRVD) and followed by pathologic neovascularization into the vitreous instead of the retina, called intravitreal neovascularization (IVNV). Therefore, the therapeutic strategy for treating ROP is to promote PRVD and inhibit or prevent IVNV. Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of ROP. There is a growing body of studies testing the use of anti-VEGF agents as a treatment for ROP. Intravitreal anti-VEGF treatment for ROP has potential advantages compared with laser photocoagulation, the gold standard for the treatment of severe ROP; however, intravitreal anti-VEGF treatment has been associated with reactivation of ROP and suppression of systemic VEGF that may affect body growth and organ development in preterm infants. Therefore, it is important to understand the role of VEGF in PRVD and IVNV. This review includes the current knowledge of anti-VEGF treatment for ROP from animal models of oxygen-induced retinopathy (OIR), highlighting the importance of VEGF inhibition by targeting retinal Müller cells, which inhibits IVNV and permits PRVD. The signaling events involved in mediating VEGF expression and promoting VEGF-mediated angiogenesis, including hypoxia-dependent signaling, erythropoietin/erythropoietin receptor-, oxidative stress-, beta-adrenergic receptor-, integrin-, Notch/Delta-like ligand 4- and exon guidance molecules-mediated signaling pathways, are also discussed.

Authors+Show Affiliations

Department of Ophthalmology, John A Moran Eye Center, The University of Utah, Salt Lake City, UT, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28539803

Citation

Wang, Haibo. "Anti-VEGF Therapy in the Management of Retinopathy of Prematurity: what We Learn From Representative Animal Models of Oxygen-induced Retinopathy." Eye and Brain, vol. 8, 2016, pp. 81-90.
Wang H. Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy. Eye Brain. 2016;8:81-90.
Wang, H. (2016). Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy. Eye and Brain, 8, 81-90. https://doi.org/10.2147/EB.S94449
Wang H. Anti-VEGF Therapy in the Management of Retinopathy of Prematurity: what We Learn From Representative Animal Models of Oxygen-induced Retinopathy. Eye Brain. 2016;8:81-90. PubMed PMID: 28539803.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy. A1 - Wang,Haibo, Y1 - 2016/05/20/ PY - 2017/5/26/entrez PY - 2017/5/26/pubmed PY - 2017/5/26/medline KW - intravitreal neovascularization KW - oxygen-induced retinopathy model KW - physiological retinal vascular development KW - retinopathy of prematurity KW - vascular endothelial growth factor SP - 81 EP - 90 JF - Eye and brain JO - Eye Brain VL - 8 N2 - Retinopathy of prematurity (ROP) remains a leading cause of childhood blindness, affecting infants born prematurely. ROP is characterized by the onset of delayed physiological retinal vascular development (PRVD) and followed by pathologic neovascularization into the vitreous instead of the retina, called intravitreal neovascularization (IVNV). Therefore, the therapeutic strategy for treating ROP is to promote PRVD and inhibit or prevent IVNV. Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of ROP. There is a growing body of studies testing the use of anti-VEGF agents as a treatment for ROP. Intravitreal anti-VEGF treatment for ROP has potential advantages compared with laser photocoagulation, the gold standard for the treatment of severe ROP; however, intravitreal anti-VEGF treatment has been associated with reactivation of ROP and suppression of systemic VEGF that may affect body growth and organ development in preterm infants. Therefore, it is important to understand the role of VEGF in PRVD and IVNV. This review includes the current knowledge of anti-VEGF treatment for ROP from animal models of oxygen-induced retinopathy (OIR), highlighting the importance of VEGF inhibition by targeting retinal Müller cells, which inhibits IVNV and permits PRVD. The signaling events involved in mediating VEGF expression and promoting VEGF-mediated angiogenesis, including hypoxia-dependent signaling, erythropoietin/erythropoietin receptor-, oxidative stress-, beta-adrenergic receptor-, integrin-, Notch/Delta-like ligand 4- and exon guidance molecules-mediated signaling pathways, are also discussed. SN - 1179-2744 UR - https://www.unboundmedicine.com/medline/citation/28539803/Anti_VEGF_therapy_in_the_management_of_retinopathy_of_prematurity:_what_we_learn_from_representative_animal_models_of_oxygen_induced_retinopathy_ L2 - https://dx.doi.org/10.2147/EB.S94449 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.